MBRX is trading 5.3% down at $3.38 as investors lock in gains following a significant multi-day run-up.
- Shares had climbed more than 20% over the past week prior to the current pullback.
- No new company-specific news or regulatory filings appeared after the close, suggesting the move is not driven by a fresh catalyst.
- The decline appears to be normal profit-taking and a reaction to broader biotech sector volatility.